Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-04
DOI
10.1038/srep10043
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens
- (2013) Christina J. Matheny et al. CHEMISTRY & BIOLOGY
- Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
- (2013) Xiaozhang Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
- (2013) Ubaldina Galli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allosteric inhibition of hypoxia inducible factor-2 with small molecules
- (2013) Thomas H Scheuermann et al. Nature Chemical Biology
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology
- (2012) Tuva B. Dahl et al. Annual Review of Nutrition
- Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells
- (2012) Su-Ryun Kim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
- (2012) He Jieyu et al. CURRENT PHARMACEUTICAL DESIGN
- CD133+EpCAM+ Phenotype Possesses More Characteristics of Tumor Initiating Cells in Hepatocellular Carcinoma Huh7 Cells
- (2012) Yi Chen et al. International Journal of Biological Sciences
- Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent Manner
- (2012) David Cerna et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: An in vitro study
- (2012) RAFAŁ JAKUB BUŁDAK et al. ONCOLOGY REPORTS
- A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase
- (2011) Ruo-Yu Zhang et al. ANALYTICAL BIOCHEMISTRY
- Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
- (2011) Uffe H Olesen et al. BMC CANCER
- Introduction
- (2011) Chao-Yu Miao CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Visfatin and Cardio–Cerebro–Vascular Disease
- (2011) Pei Wang et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Chemical Proteomics Identifies Nampt as the Target of CB30865, An Orphan Cytotoxic Compound
- (2010) Tracey C. Fleischer et al. CHEMISTRY & BIOLOGY
- The therapeutic promise of the cancer stem cell concept
- (2010) Natasha Y. Frank et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
- (2009) Anne von Heideman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Significance of CD90+ Cancer Stem Cells in Human Liver Cancer
- (2008) Zhen Fan Yang et al. CANCER CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started